0.668
0.06 (9.07%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Chromocell Therapeutics Corpora | - | - |
Stockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Average | 1.25 |
|
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 80.76% |
| % Held by Institutions | 9.43% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Sep 2024 | Announcement | Chromocell to Participate in Life Sciences Investor Forum September 19th |
| 03 Sep 2024 | Announcement | Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference |
| 07 Aug 2024 | Announcement | Chromocell Announces Stock Repurchase Plan |
| 15 Jul 2024 | Announcement | Chromocell to Participate in the Virtual Investor Lunch Break Series |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |